EUVIMEDEUVIMED entdecken
Crossref

Preventing progression to reduce costs: A cost-effectiveness analysis of enfortumab vedotin+pembrolizumab in MIBC

Constantin Rieger, Julian Heidenreich, Richard Weiten, Elena Nohl, Pia Paffenholz, Enno Storz, David Pfister, Axel Heidenreich

European Journal of Cancer · 2026-12 · 249 · 117812

DOI: 10.1016/j.ejca.2026.117812 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Cancer, 2026-12. Verfasst von Constantin Rieger und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Urologic Oncology, Robot-Assisted and Specialized Urologic Surgery, University of Cologne, Cologne, Germany. Electronic addres…. Die Arbeit nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

Cost-effectiveness analysisEnfortumab vedotinMuscle-invasive bladder cancerPembrolizumab

Autor:innen und Institutionen

  • Department of Urology, Urologic Oncology, Robot-Assisted and Specialized Urologic Surgery, University of Cologne, Cologne, Germany. Electronic address: constantin.rieger@uk-koeln.de.
  • Department of Urology, Urologic Oncology, Robot-Assisted and Specialized Urologic Surgery, University of Cologne, Cologne, Germany.
  • Department of Urology, Urologic Oncology, Robot-Assisted and Specialized Urologic Surgery, University of Cologne, Cologne, Germany; Center for Integrated Oncology (CIO) Köln-Bonn, Cologne, Germany.
  • Department of Urology, Urologic Oncology, Robot-Assisted and Specialized Urologic Surgery, University of Cologne, Cologne, Germany; Department of Urology, Medical University Vienna, Austria.

Zitieren

APA

Rieger, C., Heidenreich, J., Weiten, R., Nohl, E., Paffenholz, P., Storz, E., Pfister, D., & Heidenreich, A. (2026). Preventing progression to reduce costs: A cost-effectiveness analysis of enfortumab vedotin+pembrolizumab in MIBC. European Journal of Cancer, 249, 117812. https://doi.org/10.1016/j.ejca.2026.117812

Vancouver

Rieger C, Heidenreich J, Weiten R, Nohl E, Paffenholz P, Storz E, et al. Preventing progression to reduce costs: A cost-effectiveness analysis of enfortumab vedotin+pembrolizumab in MIBC. European Journal of Cancer. 2026;249:117812. doi:10.1016/j.ejca.2026.117812

BibTeX
@article{Rieger2026,
  author = {Rieger, Constantin and Heidenreich, Julian and Weiten, Richard and Nohl, Elena and Paffenholz, Pia and Storz, Enno and Pfister, David and Heidenreich, Axel},
  title = {Preventing progression to reduce costs: A cost-effectiveness analysis of enfortumab vedotin+pembrolizumab in MIBC},
  journal = {European Journal of Cancer},
  year = {2026},
  volume = {249},
  pages = {117812},
  doi = {10.1016/j.ejca.2026.117812}
}
Kostenlos starten →